Leading Innovation Platform:
Innovation-driven + Patent protection + Market transformation
Innovation-driven
By combining independent innovation and collaborative research with domestic and foreign top institutions, explore novel markers, develop innovative technologies and products.
Patent protection
Relying on the management team with extensive experience on patent protection, carry out comprehensive patent protection for innovative markers and developed technical platforms, products and methods
Market transformation
Based on the market barriers and competitive advantages brought by patent barriers, through a marketing strategy combining self-owned domestic and foreign channels and authorized multinational companies, commercialize innovative diagnostic products and technologies globally
By building a novel innovation platform, Shuwen and its top partners in many countries or regions around the world have jointly developed forward-looking innovative diagnostic products, forming an advanced technology development model based on China and facing the world, which brings sustainable innovation capability to Shuwen. CapCord® Pre-Eclampsia detection kit is one of the examples of Shuwen’s innovation platform. This kit is a first-in-class and China-originated product developed by Shuwen in cooperation with Yale University based on a novel, patented biomarker “misfolded protein”. Shuwen exclusively authorized this product to Perkin Elmer, an international IVD industry giant and a global leader in maternal and infant diagnosis. This transaction was evaluated by McKinsey in its annual report on China’s medical technology field as “a typical representative of the new era of global cooperation for Chinese companies in the medical technology industry”.
PRODUCT RESEARCH & DEVELOPMENT
UNIVERSITIES AND RESEARCH INSTITUTIONS
MARKET EXPANSION AND DEVELOPMENT
MEDICAL INSTITUTIONS
Patents protection is the driving force behind innovation in precision diagnostic products
Founder Talks
Jay Z. Zhang, M.S., J.D.,
American lawyer, patent attorney, expert of the national “Thousand Talents Program”, distinguished professor of China Jiliang University Law School, current chairman of Zhejiang Shuwen Biotechnology Co., Ltd.;
Editorial Board Member, Biotechnology Law Report (SCI Indexed Journal); Former Intellectual Property Director, Vice President and Senior Vice President of Myriad Genetics in the United States, taught biotechnology patent law, chemical patent law and international patent law at the University of Utah, the University of Washington, Harward University and other law schools.
He has more than 20 years of experience as a lawyer in the United States, and holds the bar license of the United States Supreme Court, the United States Court of Appeals for the Federal Circuit, and the patent attorney license of the United States Patent and Trademark Office; He has led a number of intellectual property litigation cases that directly affect relevant important policies and legislation in the United States, and once led the “gene patent case” that attracted the attention of mainstream media, patent and biotechnology industries in the United States, and was ranked first among the top 5 most life-changing cases in 2013 by Business Insider magazine;
From 2002 to 2008, he won the case about European patent dispute for breast cancer genetic testing, which was estimated by Nature magazine as “the most difficult and complex biotechnology patent case in the history of the European Patent Office”; He first initiated and participated in the legislation of U.S. Public Law No. 110-85 on the protection of new drugs in the United States, participated in the compilation of the American MBA textbook Biotechnology Entrepreneurship (Academic Press 2014 2020 Edited by Craig Shimasaki), and is the main author of the part on biomedical patent protection and enterprise intellectual property management;
He has delivered more than 20 speeches and reports on intellectual property management and protection at international conferences in Europe and the United States, and is a member of the Joint Association of Patent Directors of Large and Medium-sized Enterprises (ACPC), the chairman of the International Department of the Enterprise Committee of the American Intellectual Property Lawyers Association (AIPLA), and the vice chairman of the China Committee of the American Chapter of the Association for the Protection of Intellectual Property (AIPPI).
